<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7904301</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4537</journal-id>
<journal-id journal-id-type="nlm-ta">J Autism Dev Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">J Autism Dev Disord</journal-id>
<journal-title-group>
<journal-title>Journal of autism and developmental disorders</journal-title>
</journal-title-group>
<issn pub-type="ppub">0162-3257</issn>
<issn pub-type="epub">1573-3432</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29536216</article-id>
<article-id pub-id-type="pmc">6394231</article-id>
<article-id pub-id-type="doi">10.1007/s10803-018-3536-7</article-id>
<article-id pub-id-type="manuscript">NIHMS950880</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lewis</surname>
<given-names>Alan S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Schalkwyk</surname>
<given-names>Gerrit Ian</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lopez</surname>
<given-names>Mayra Ortiz</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Volkmar</surname>
<given-names>Fred R.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Picciotto</surname>
<given-names>Marina R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sukhodolsky</surname>
<given-names>Denis G.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
<aff id="A2"><label>2</label>Child Study Center, Yale University School of Medicine, New Haven, Connecticut, USA</aff>
<aff id="A3"><label>3</label>Present address: Butler Hospital, Providence, Rhode Island, USA</aff>
<author-notes>
<fn fn-type="con" id="FN1">
<p id="P1">Author contributions</p>
<p id="P2">ASL and GIvS conceived of the study, participated in its design, coordination, and data collection, and drafted the manuscript; MOL participated in the coordination of the study and 2performed data collection; FRV, MRP, and DGS participated in the design of the study and interpretation of the results. All authors read and approved the final manuscript.</p>
</fn>
<corresp id="CR1"><label>*</label><bold>Corresponding Author:</bold> Alan S. Lewis, M.D., Ph.D., Department of Psychiatry, Yale University School of Medicine, 184 Liberty Street, Room LV120, New Haven, Connecticut 06519, USA, <email>alan.lewis@yale.edu</email>, Telephone: 203-737-2041, Fax: 203-737-2043</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P28">Conflict of interest</p>
<p id="P29">The authors declare no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>15</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2019</year>
</pub-date>
<volume>48</volume>
<issue>8</issue>
<fpage>2748</fpage>
<lpage>2757</lpage>
<!--elocation-id from pubmed: 10.1007/s10803-018-3536-7-->
<abstract id="ABS1">
<p id="P3">Nicotinic acetylcholine receptors (nAChRs), particularly the Î±7 nAChR, are implicated in the pathophysiology of both autism spectrum disorder (ASD) and aggressive behavior. We explored the feasibility, tolerability, and preliminary efficacy of targeting nAChRs using transdermal nicotine to reduce aggressive symptoms in adults with ASD. Eight subjects were randomized in a double-blind crossover trial of seven milligrams transdermal nicotine or placebo, each for one week. All participants tolerated nicotine treatment well. Five subjects contributed data to the primary outcome, Aberrant Behavior Checklist-Irritability (ABC-I) subscale change from baseline, which was improved by nicotine compared to placebo. Sleep ratings were also improved by nicotine and correlated with ABC-I improvement. These findings support further investigation of nAChR agonists for aggression and sleep in ASD.</p>
</abstract>
<kwd-group>
<kwd>Nicotine</kwd>
<kwd>nicotinic acetylcholine receptor</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>aggression</kwd>
<kwd>irritability</kwd>
<kwd>adult</kwd>
<kwd>sleep</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>